FNCH实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States...

Stats
今日成交量	53 317.00
平均成交量	47 069.00
市值	3.69M
EPS	$0 ( 2024-03-28 )
下一个收益日期	( $0 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0500
ATR14	$0.0560 (2.43%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Smisek Jeffery A	Sell	1 600	Common Stock
2024-03-28	Smisek Jeffery A	Sell	6 642	Common Stock
2023-11-22	Smisek Jeffery A	Sell	1 470	Common Stock
2023-06-09	Blischak Matthew P.	Buy	962 899	Stock Option (right to buy)
2023-06-08	Blischak Matthew P.	Buy	962 899	Stock Option (right to buy)

INSIDER POWER
97.82
Last 84 transactions
Buy: 22 938 760 \| Sell: 28 923 806

Finch Therapeutics Group, 相关性

10 最正相关
ACET	0.917
VNDA	0.917
AFMD	0.914
COMT	0.91
GROM	0.903
EQRX	0.889
STRC	0.889
VRAY	0.886
KSPN	0.885
AYLA	0.883

10 最负相关
ROVR	-0.879
NVCN	-0.878
FTIV	-0.876
TIOAU	-0.873
XM	-0.873
ATVI	-0.873
BHAC	-0.868
IDLB	-0.867
APXI	-0.867
PAYA	-0.867

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Finch Therapeutics Group, 相关性 - 货币/商品

0.53
( weak )

0.35
( neutral )

0.00
( neutral )

0.35
( neutral )

0.48
( neutral )

0.36
( neutral )

Finch Therapeutics Group, 财务报表

Annual	2023
营收:	$107 000
毛利润:	$-1.41M (-1 320.56 %)
EPS:	$-46.59

FY	2023
营收:	$107 000
毛利润:	$-1.41M (-1 320.56 %)
EPS:	$-46.59

FY	2022
营收:	$861 000
毛利润:	$-4.65M (-539.61 %)
EPS:	$-71.52

FY	2021
营收:	$18.53M
毛利润:	$18.53M (100.00 %)
EPS:	$-1.676

Financial Reports:

No articles found.

Finch Therapeutics Group,

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

实时更新： Finch Therapeutics Group, [FNCH]

Upcoming Earnings Alert